Trial Profile
A Clinical Study to Evaluate the Efficacy and Safety of JR-031 in Patients with Epidermolysis Bullosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Epidermolysis bullosa; Skin ulcer
- Focus Registrational; Therapeutic Use
- 22 Mar 2019 According to a JCR Pharmaceuticals media release, the company has filed an application with the Ministry of Health, Labour and Welfare of Japan (MHLW) for additional marketing approval of TEMCELL HS Inj. (TEMCELL), for the indication of epidermolysis bullosa, based on the results of this trial.
- 29 Oct 2018 According to a JCR Pharmaceuticals media release, the company will prepare the regulatory application of JR-031EB by the end of FY 2018 for an expanded indication of Epidermolysis Bullosa, based on the results of this trial.
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.